Challenges and opportunities with two different onco modalities
Paris, 2022
With the AACR annual meeting coming up next month, it seemed a good opportunity to highlight some relevant findings from another cancer conference held this week (ESMO Targeted Anticancer Therapies congress or TAT for short) as a warm-up for the bigger event since there is some handy overlap topic wise.
Having very recently been in Paris (TAT changed to a virtual only meeting), I can say it didn’t feel very spring-like at all (right), quite the opposite!
Europe continues under a cloud at the moment with the Ukraine war very much to the fore – European Lung has also been moved to a virtual event as the conference venue in Prague is quite rightly being converted into a refugee assistance centre.
Despite all the prevailing gloom, there were quite a few important nuggets of interest to share from TAT this year…
BSB subscribers can read our latest commentary – you can either log-in or click to access.
This content is restricted to subscribers
